James Wymer, MD, FAAN
Professor & Division Chief; Melvin Greer Professor
Department:
MD-NEUROMUSCULAR NEUROLOGY
Business Phone:
(352) 273-5550
Business Email:
james.wymer@neurology.ufl.edu
About James Wymer
My name is Dr. James Wymer, I’m a neurologist and professor practicing at the University of Florida. I specialize in diagnosis and management of neuromuscular diseases, including amyotrophic lateral sclerosis (ALS) or Lou Gehrig’s disease, muscle diseases, and peripheral neuropathies. I have extensive experience in clinical research, having been a principal investigator on numerous clinical trials, including studies of ALS, diabetic neuropathy, multiple sclerosis, migraine headaches, and epilepsy. I am a fellow of the American Academy of Neurology (AAN) and the American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM), as well as a member of several national consortiums to research neuropathic pain and ALS.
My clinical interests include: • ALS or Lou Gehrig’s Disease • Neuromuscular diseases • Hereditary Neuropathy • Muscle disease • Multiple Sclerosis • Diabetic neuropathy • Migraine headaches • Neurofibromatosis
Teaching Profile
Courses Taught
2021
PAS5020 Intro to Medicine 2
2021
MDC7800 Neurology Clerkship
Board Certifications
-
NeurologyAmerican Board of Psychiatry and Neurology
Clinical Profile
Specialties
- Neurology
Subspecialties
- Neuromuscular Medicine
Areas of Interest
- Amyotrophic lateral sclerosis (ALS)
- Migraine
- Multiple sclerosis
- Neurofibromatosis 2
- Neurofibromatosis-1
- Neuromuscular disorders
- Peripheral neuropathy
Research Profile
Areas of Interest
- ALS
- Muscular dystrophy
- Neuropathy
Open Researcher and Contributor ID (ORCID)
0000-0003-0809-2977
Publications
2024
Diagnoses of muscular dystrophy in a veterans health system.
Muscle & nerve.
70(2):273-278
[DOI] 10.1002/mus.28112.
[PMID] 38783566.
2024
Relationship between pulmonary, cough, and swallowing functions in individuals with amyotrophic lateral sclerosis.
Muscle & nerve.
70(1):140-147
[DOI] 10.1002/mus.28113.
[PMID] 38742544.
2023
Dextromethorphan/quinidine for the treatment of bulbar impairment in amyotrophic lateral sclerosis.
Annals of clinical and translational neurology.
10(8):1296-1304
[DOI] 10.1002/acn3.51821.
[PMID] 37265174.
2023
Functional Lingual Pressure Thresholds for Swallowing Safety and Efficiency Impairments in Amyotrophic Lateral Sclerosis.
Dysphagia.
38(2):676-685
[DOI] 10.1007/s00455-022-10499-1.
[PMID] 35907088.
2023
Maximum lingual pressure impacts both swallowing safety and efficiency in individuals with amyotrophic lateral sclerosis
Neurogastroenterology & Motility.
35(4)
[DOI] 10.1111/nmo.14521.
[PMID] 36573040.
2023
Maximum Phonation Time as a Surrogate Marker for Airway Clearance Physiologic Capacity and Pulmonary Function in Individuals With Amyotrophic Lateral Sclerosis.
Journal of speech, language, and hearing research : JSLHR.
66(4):1165-1172
[DOI] 10.1044/2022_JSLHR-22-00522.
[PMID] 36877985.
2023
Oral Edaravone – Introducing a Flexible Treatment Option for Amyotrophic Lateral Sclerosis.
Expert review of neurotherapeutics.
23(10):859-866
[DOI] 10.1080/14737175.2023.2251687.
[PMID] 37646130.
2023
Pharmacokinetics, Bioavailability, and Swallowing Safety With Riluzole Oral Film.
Clinical pharmacology in drug development.
12(1):57-64
[DOI] 10.1002/cpdd.1168.
[PMID] 36168148.
2023
Predictors of Peak Expiratory Cough Flow in Individuals with Amyotrophic Lateral Sclerosis.
Dysphagia.
38(2):719-725
[DOI] 10.1007/s00455-022-10503-8.
[PMID] 35931882.
2023
Primary lateral sclerosis natural history study – planning, designing, and early enrollment.
Amyotrophic lateral sclerosis & frontotemporal degeneration.
24(5-6):394-404
[DOI] 10.1080/21678421.2022.2161912.
[PMID] 36576200.
2023
Profiles of Dysarthria and Dysphagia in Individuals With Amyotrophic Lateral Sclerosis.
Journal of speech, language, and hearing research : JSLHR.
66(1):154-162
[DOI] 10.1044/2022_JSLHR-22-00312.
[PMID] 36525626.
2023
Profiling Number of Swallows per Bolus and Residue in Individuals With Amyotrophic Lateral Sclerosis.
Journal of speech, language, and hearing research : JSLHR.
66(10):3763-3772
[DOI] 10.1044/2023_JSLHR-23-00209.
[PMID] 37591233.
2023
Respiratory Strength Training in Amyotrophic Lateral Sclerosis
Neurology.
100(15)
[DOI] 10.1212/wnl.0000000000206830.
2023
Respiratory therapies for Amyotrophic Lateral Sclerosis: A state of the art review.
Chronic respiratory disease.
20
[DOI] 10.1177/14799731231175915.
[PMID] 37219417.
2023
Sensitivity and specificity of the Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised to detect dysarthria in individuals with amyotrophic lateral sclerosis.
Muscle & nerve.
68(3):296-302
[DOI] 10.1002/mus.27923.
[PMID] 37345346.
2023
Temporal serum metabolomic and lipidomic analyses distinguish patients with access-related hand disability following arteriovenous fistula creation.
Scientific reports.
13(1)
[DOI] 10.1038/s41598-023-43664-z.
[PMID] 37798334.
2023
The natural history of ALS: Baseline characteristics from a multicenter clinical cohort
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration.
24(7-8):625-633
[DOI] 10.1080/21678421.2023.2232812.
2022
Acute intermittent hypoxia and respiratory muscle recruitment in people with amyotrophic lateral sclerosis: A preliminary study.
Experimental neurology.
347
[DOI] 10.1016/j.expneurol.2021.113890.
[PMID] 34624328.
2022
Blood-based biomarkers of inflammation in amyotrophic lateral sclerosis
Molecular Neurodegeneration.
17(1)
[DOI] 10.1186/s13024-022-00515-1.
[PMID] 35073950.
2022
Discriminant ability of the 3-ounce water swallow test to detect aspiration in amyotrophic lateral sclerosis.
Neurogastroenterology and motility.
34(7)
[DOI] 10.1111/nmo.14310.
[PMID] 34936158.
2022
Discriminant Ability of the Eating Assessment Tool-10 to Detect Swallowing Safety and Efficiency Impairments.
The Laryngoscope.
132(12):2319-2326
[DOI] 10.1002/lary.30043.
[PMID] 35137963.
2022
Effect of sodium phenylbutyrate/taurursodiol on tracheostomy/ventilation-free survival and hospitalisation in amyotrophic lateral sclerosis: long-term results from the CENTAUR trial.
Journal of neurology, neurosurgery, and psychiatry.
93(8):871-5
[DOI] 10.1136/jnnp-2022-329024.
[PMID] 35577511.
2022
Swallowing Safety and Efficiency Impairment Profiles in Individuals with Amyotrophic Lateral Sclerosis.
Dysphagia.
37(3):644-654
[DOI] 10.1007/s00455-021-10315-2.
[PMID] 34037850.
2021
A case of diffuse midline glioma with histone H3 K27M mutation mimicking long segmental myelitis
Interdisciplinary Neurosurgery.
23
[DOI] 10.1016/j.inat.2020.101005.
2021
A Phase 2, Double-Blind, Randomized, Dose-Ranging Trial Of Reldesemtiv In Patients With ALS.
Amyotrophic lateral sclerosis & frontotemporal degeneration.
22(3-4):287-299
[DOI] 10.1080/21678421.2020.1822410.
[PMID] 32969758.
2021
Long-term survival of participants in the CENTAUR trial of sodium phenylbutyrate-taurursodiol in amyotrophic lateral sclerosis.
Muscle & nerve.
63(1):31-39
[DOI] 10.1002/mus.27091.
[PMID] 33063909.
2021
Patient Assisted Intervention for Neuropathy: Comparison of Treatment in Real Life Situations (PAIN-CONTRoLS): Bayesian Adaptive Comparative Effectiveness Randomized Trial.
JAMA neurology.
78(1):68-76
[DOI] 10.1001/jamaneurol.2020.2590.
[PMID] 32809014.
2021
Reflexive Airway Sensorimotor Responses in Individuals with Amyotrophic Lateral Sclerosis.
Dysphagia.
36(4):574-582
[DOI] 10.1007/s00455-020-10171-6.
[PMID] 32778945.
2020
Clinical care and therapeutic trials in PLS.
Amyotrophic lateral sclerosis & frontotemporal degeneration.
21(sup1):67-73
[DOI] 10.1080/21678421.2020.1837180.
[PMID] 33602017.
2020
Diagnostic utility of the amyotrophic lateral sclerosis Functional Rating Scale-Revised to detect pharyngeal dysphagia in individuals with amyotrophic lateral sclerosis.
PloS one.
15(8)
[DOI] 10.1371/journal.pone.0236804.
[PMID] 32790801.
2020
Management of Primary Lateral Sclerosis
Current Treatment Options in Neurology.
22(10)
[DOI] 10.1007/s11940-020-00640-6.
2020
Preface: promoting research in PLS: current knowledge and future challenges.
Amyotrophic lateral sclerosis & frontotemporal degeneration.
21(sup1):1-2
[DOI] 10.1080/21678421.2020.1840795.
[PMID] 33602018.
2020
Sleep disorders in myotonic dystrophies.
Muscle & nerve.
62(3):309-320
[DOI] 10.1002/mus.26866.
[PMID] 32212331.
2020
Trial of Sodium Phenylbutyrate-Taurursodiol for Amyotrophic Lateral Sclerosis.
The New England journal of medicine.
383(10):919-930
[DOI] 10.1056/NEJMoa1916945.
[PMID] 32877582.
2019
Provisional best practices guidelines for the evaluation of bulbar dysfunction in amyotrophic lateral sclerosis.
Muscle & nerve.
59(5):531-536
[DOI] 10.1002/mus.26408.
[PMID] 30620104.
2018
Best practices protocol for the evaluation of bulbar dysfunction: summary recommendations from the NEALS bulbar subcommittee symposium.
Amyotrophic lateral sclerosis & frontotemporal degeneration.
19(3-4):311-312
[DOI] 10.1080/21678421.2017.1404109.
[PMID] 29205054.
2018
Combined respiratory training in an individual with C9orf72 amyotrophic lateral sclerosis.
Annals of clinical and translational neurology.
5(9):1134-1138
[DOI] 10.1002/acn3.623.
[PMID] 30250869.
2018
Targeting the Neuromuscular Junction in ALS.
Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics.
15(3):713-714
[DOI] 10.1007/s13311-018-0647-y.
[PMID] 30006767.
2017
Enhanced Bulbar Function in Amyotrophic Lateral Sclerosis: The Nuedexta Treatment Trial.
Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics.
14(3):762-772
[DOI] 10.1007/s13311-016-0508-5.
[PMID] 28070747.
2017
Erratum to: Enhanced Bulbar Function in Amyotrophic Lateral Sclerosis: The Nuedexta Treatment Trial.
Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics.
14(3)
[DOI] 10.1007/s13311-017-0517-z.
[PMID] 28283968.
2017
Increasing Evidence for an Association Between Amyotrophic Lateral Sclerosis and Psychiatric Disorders.
JAMA neurology.
74(12):1396-1398
[DOI] 10.1001/jamaneurol.2017.1920.
[PMID] 29049449.
2017
Paraneoplastic Lambert-Eaton Myasthenic Syndrome With Limbic Encephalitis: Clinical Correlation With the Coexistence of Anti-VGCC and Anti-GABAB Receptor Antibodies.
Journal of clinical neuromuscular disease.
19(2):84-88
[DOI] 10.1097/CND.0000000000000192.
[PMID] 29189554.
2017
The evaluation of bulbar dysfunction in amyotrophic lateral sclerosis: survey of clinical practice patterns in the United States.
Amyotrophic lateral sclerosis & frontotemporal degeneration.
18(5-6):351-357
[DOI] 10.1080/21678421.2017.1313868.
[PMID] 28425762.
2015
Double-blind, placebo-controlled study of HGF gene therapy in diabetic neuropathy.
Annals of clinical and translational neurology.
2(5):465-78
[DOI] 10.1002/acn3.186.
[PMID] 26000320.
2014
An open-label multicenter study to assess the safety of dextromethorphan/quinidine in patients with pseudobulbar affect associated with a range of underlying neurological conditions.
Current medical research and opinion.
30(11):2255-65
[DOI] 10.1185/03007995.2014.940040.
[PMID] 25062507.
2011
Keratinocyte expression of calcitonin gene-related peptide β: implications for neuropathic and inflammatory pain mechanisms.
Pain.
152(9):2036-2051
[DOI] 10.1016/j.pain.2011.04.033.
[PMID] 21641113.
2009
Efficacy and safety of lacosamide in diabetic neuropathic pain: an 18-week double-blind placebo-controlled trial of fixed-dose regimens.
The Clinical journal of pain.
25(5):376-85
[DOI] 10.1097/AJP.0b013e318196d2b6.
[PMID] 19454870.
2006
Dextromethorphan and quinidine in adult patients with uncontrolled painful diabetic peripheral neuropathy: a 29-day, multicenter, open-label, dose-escalation study.
Clinical therapeutics.
28(10):1607-18
[PMID] 17157116.
2006
Randomized, controlled trial of dextromethorphan/quinidine for pseudobulbar affect in multiple sclerosis.
Annals of neurology.
59(5):780-7
[PMID] 16634036.
Grants
Dec 2023
ACTIVE
ALS/MND NATURAL HISTORY REPOSITORY SITE AGREEMENT
Role: Principal Investigator
Funding: MASSACHUSETTS GENERAL HOSPITAL
Sep 2023
ACTIVE
Multimodal longitudinal imaging of brain and cervical cord as ALS disease biomarker using microstructure statistics and morphometry
Role: Principal Investigator
Funding: UNIV OF MINNESOTA
via US FOOD AND DRUG ADMN
Sep 2023
ACTIVE
Clinic-based Multicenter ALS Natural History Data Collection- Supplement
Role: Principal Investigator
Funding: UNIV OF MINNESOTA
via US FOOD AND DRUG ADMN
Sep 2023
ACTIVE
Safety of Metformin in C9orf72 ALS: Effects on RAN Proteins, Breathing, Imaging, and Metabolomic Outcome Measures
Role: Co-Investigator
Funding: US ARMY MED RES ACQUISITION
Apr 2023
ACTIVE
A Phase 2, randomised, double-blind, placebo-controlled, 2-way
crossover study to evaluate the efficacy, safety, and tolerability of
NMD670 in ambulatory adults with Type 3 spinal muscular
atrophy
Role: Principal Investigator
Funding: NMD PHARMA
Dec 2022
ACTIVE
Safety & therapeutic potential of metformin for C9orf72 ALS
Role: Co-Investigator
Funding: AMYOTROPHIC LATERAL SCLEROSIS ASSOC
Nov 2022
ACTIVE
CTOA Wymer
Role: Principal Investigator
Funding: UNIV OF FLORIDA
Sep 2022
ACTIVE
Clinic-based Multicenter ALS Natural History Data Collection
Role: Principal Investigator
Funding: UNIV OF MINNESOTA
via US FOOD AND DRUG ADMN
Aug 2022
ACTIVE
A Phase 3b, Multicenter, Randomized, Double-blind Extension Study to Evaluate the Continued Efficacy and Safety of Oral Edaravone Administered for an Additional Period of up to 48 Weeks Following Study MT-1186-A02 in Subjects with Amyotrophic Lateral Sclerosis (ALS)
Role: Principal Investigator
Funding: ICON CLINICAL RESEARCH INC
via MITSUBISHI TANABE PHARMA DEVELOPMENT
Aug 2022
– Jul 2024
PLS Natural History Project 2
Role: Principal Investigator
Funding: COLUMBIA UNIVERSITY MEDICAL CENTER
via AMYOTROPHIC LATERAL SCLEROSIS ASSOC
Jul 2022
ACTIVE
Identifying and targeting novel repeat associated non-AUG (RAN) proteins in sporadic ALS
Role: Co-Investigator
Funding: US ARMY MED RES ACQUISITION
Jul 2022
ACTIVE
Novel repeat associated non-AUG (RAN) proteins in sALS, sFTD and SBMA: shared pathological features and unifying therapeutic opportunities
Role: Co-Investigator
Funding: NATL INST OF HLTH NINDS
Jun 2022
ACTIVE
An Intermediate size, Expanded Access Protocol to Provide AMX0035, a Fixed Combination of Sodium Phenylbutyrate (PB) and Taurursodiol (TURSO), for the Treatment of Adult Patients with Amyotrophic Lateral Sclerosis (ALS)
Role: Principal Investigator
Funding: BIONICAL LTD
via AMYLYX PHARMACEUTICALS
Jan 2022
ACTIVE
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of AMX0035 Versus Placebo for 48-week Treatment of Adult Patients with Amyotrophic Lateral Sclerosis (ALS)
Role: Principal Investigator
Funding: PEACHTREE BIORESEARCH SOLUTIONS
via AMYLYX PHARMACEUTICALS
Jan 2022
ACTIVE
Acute adenosine receptor antagonism to promote breathing plasticity in ALS
Role: Co-Investigator
Funding: AMYOTROPHIC LATERAL SCLEROSIS ASSOC
Jul 2021
ACTIVE
CTOA – Multiple Sclerosis
Role: Principal Investigator
Funding: UNIV OF FLORIDA
May 2021
ACTIVE
Phase 2a Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic study of Intravenous ANX005 in Subjects with Amyotrophic Lateral Sclerosis
Role: Principal Investigator
Funding: WORLDWIDE CLINICAL TRIALS
via ANNEXON
Apr 2021
ACTIVE
A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Study to Assess the Efficacy, Safety, and Tolerability of PXT3003 in
Charcot-Marie-Tooth Type 1A (CMT1A)
Role: Principal Investigator
Funding: PHARNEXT
Mar 2021
– Dec 2023
A Phase 3b, Multicenter, Randomized, Double-Blind Study to Evaluate Efficacy and Safety of Oral Edaravone Administered for a Period of 48 Weeks in Subjects with Amyotrophic Lateral Sclerosis (ALS)
Role: Principal Investigator
Funding: ICON CLINICAL RESEARCH INC
via MITSUBISHI TANABE PHARMA DEVELOPMENT
Dec 2020
– Nov 2023
A Phase 3, Multi-Center, Open-label, Safety Extension Study of Oral Edaravone Administered over 96 Weeks in Subjects with Amyotrophic Lateral Sclerosis (ALS)
Role: Principal Investigator
Funding: ICON CLINICAL RESEARCH INC
via MITSUBISHI TANABE PHARMA DEVELOPMENT
Nov 2020
– Dec 2023
A pharmacokinetic and pharmacodynamic study of AMX0035 in patients with ALS
Role: Principal Investigator
Funding: AMYLYX PHARMACEUTICALS
Oct 2020
ACTIVE
A Compassionate Use Protocol of AMX0035 for treatment of patients with Amyotrophic Lateral Sclerosis
Role: Principal Investigator
Funding: UNITED BIOSOURCE
via AMYLYX PHARMACEUTICALS
Jul 2020
– Jul 2022
PLS Natural History Study (PNHS)
Role: Principal Investigator
Funding: COLUMBIA UNIVERSITY
via SPASTIC PARAPLEGIA FOUNDATION
Feb 2020
– Nov 2022
A Phase 3, Multi-center, Open-label, Safety Study of Oral Edaravone Administered over 48 Weeks in Subjects with Amyotrophic Lateral Sclerosis (ALS)
Role: Principal Investigator
Funding: ICON CLINICAL RESEARCH INC
via MITSUBISHI TANABE PHARMA DEVELOPMENT
Jan 2020
– Jan 2025
Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients with ALS: Open-Label Extension for Patients Completing Study 3119002
Role: Principal Investigator
Funding: PHARMACEUTICAL RES ASSO
via ORION CORP
Jan 2020
ACTIVE
HEALEY ALS Platform Trial Regimen-Specific Appendix (RSA) A to Master Protocol, ZILUCOPLAN | Home Spirometry and Open-Label Extension (OLE) Period (add'l support for TO2)
Role: Principal Investigator
Funding: MASSACHUSETTS GENERAL HOSPITAL
via RA PHARMACEUTICALS
Jan 2020
ACTIVE
Platform Trial for the Treatment of Amyotrophic Lateral Sclerosis (A
LS): A perpetual multi-center, multi-regimen, clinical trial evaluating
the safety and efficacy of investigational products for the treatment
of ALS
Role: Principal Investigator
Funding: MASSACHUSETTS GENERAL HOSPITAL
Jan 2020
– Dec 2021
Quality of Life Grant MS Foundation
Role: Principal Investigator
Funding: MULTIPLE SCLEROSIS FOUNDATION
Jan 2020
– Jun 2020
Natural History Pilot Project- University of Florida
Role: Principal Investigator
Funding: AMYOTROPHIC LATERAL SCLEROSIS ASSOC
Sep 2019
ACTIVE
Surveillance of muscular dystrophy in the Southeastern United States
Role: Co-Investigator
Funding: CTRS FOR DISEASE CONTROL AND PREVENTION
Nov 2018
ACTIVE
CTOA – General
Role: Principal Investigator
Funding: UNIV OF FLORIDA
Aug 2018
– Aug 2023
EFFECTS OF ORAL LEVOSIMENDAN (ODM-109) ON RESPIRATORY FUNCTION IN PATIENTS WITH ALS
Role: Principal Investigator
Funding: PRA HEALTH SCIENCES
via ORION CORP
Apr 2018
– Feb 2023
Evaluation of the Safety, Tolerability, Efficacy and Activity of AMX0035, a Fixed Combination of Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA), for Treatment of Amyotrophic Lateral Sclerosis (ALS), Open Label Extension
Role: Principal Investigator
Funding: AMYLYX PHARMACEUTICALS
Jan 2018
– Jan 2023
A Phase 2, Multi-Center, Double-Blind, Randomized, Dose-Ranging, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of CK 2127107 in Patients with Amyotrophic Lateral Sclerosis (ALS)
Role: Principal Investigator
Funding: PAREXEL INTERNATIONAL PTY
via CYTOKINETICS INC
Jan 2018
– Jan 2023
A Single Center Study to Evaluate the Effect of Riluzole Oral Soluble Film on Swallowing Safety in Individuals With Amyotrophic Lateral Sclerosis
Role: Principal Investigator
Funding: INVENTIV HEALTH CLINICAL LLC
via AQUESTIVE THERAPEUTICS
Dec 2017
– Dec 2022
A multicenter, 18-week open label safety and efficacy trial of Dalfampridine in primary lateral sclerosis
Role: Principal Investigator
Funding: HOSPITAL FOR SPECIAL SURGERY
via NORTHEAST ALS ASSO
Nov 2017
– Nov 2018
A Randomized, Double-Blind, Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of FLX-787-ODT for Treatment of Muscle Cramps in Adult Subjects with Charcot-Marie-Tooth Disease
Role: Principal Investigator
Funding: FLEX PHARMA INC
Oct 2017
– Oct 2022
A Multicenter, Double Blind, Placebo Controlled Study to Assess the Efficacy and Safety of H.P. Acthar? Gel in the Treatment of Subjects With Amyotrophic Lateral Sclerosis
Role: Principal Investigator
Funding: *MALLINCKRODT PHARMACEUTICALS-Bankrupt
Jul 2017
– Aug 2023
Evaluation of the Safety, Tolerability, Efficacy and Activity of AMX0035, a Fixed Combination of Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA) for a Treatment of Amyotropic Lateral Sclerosis (ALS)
Role: Principal Investigator
Funding: MASSACHUSETTS GENERAL HOSPITAL
via AMYOTROPHIC LATERAL SCLEROSIS ASSOC
Jul 2017
– May 2022
A Program to develop a research database for the study of abnormal cellular components in Myasthenia Gravis: Specimen banking and data registry
Role: Principal Investigator
Funding: UF FOUNDATION
Apr 2017
– Mar 2023
Delineating Physiologic Mechanisms of Swallowing impairment and Decline in ALS
Role: Co-Investigator
Funding: NATL INST OF HLTH NINDS
Jul 2016
– Jul 2021
A Phase III, Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Safety and Efficacy of VM202 in Subjects with Painful Diabetic Peripheral Neuropathy
Role: Principal Investigator
Funding: VIROMED CO LTD
Apr 2014
– Sep 2018
Patient Assisted Intervention for Neuropathy: Comparison of Treatment in Real Life Situations (PAIN-CONTRoLS)
Role: Principal Investigator
Funding: UNIV OF KANSAS MEDICAL CTR
via PATIENT-CENTERED OUTCOMES RES INST
Education
Medical Degree
1984-1991
·
University of Maryland
Contact Details
Phones:
- Business:
- (352) 273-5550
Emails:
- Business:
- james.wymer@neurology.ufl.edu
Addresses:
- Business Mailing:
-
PO Box 100268
GAINESVILLE FL 32610 - Business Street:
-
3011 SW WILLISTON RD RM 1103
GAINESVILLE FL 32608